Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Journal

Back to Journal Articles

Elective IABP Insertion May Not Improve Post-PCI Outcome

Last Updated: August 24, 2010.

 

Similar rate of major events found in patients who do, do not receive intra-aortic balloon pump

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Elective intra-aortic balloon pump insertion does not appear to improve outcomes after high-risk percutaneous coronary intervention, according to a study in the Aug. 25 issue of the Journal of the American Medical Association.

TUESDAY, Aug. 24 (HealthDay News) -- Elective intra-aortic balloon pump (IABP) insertion does not appear to improve outcomes after high-risk percutaneous coronary intervention (PCI), according to a study in the Aug. 25 issue of the Journal of the American Medical Association.

Divaka Perera, M.D., of King's College London, and colleagues studied outcomes in patients with severe left ventricular dysfunction and extensive coronary disease who underwent PCI, 151 of whom received elective IABP and 150 of whom did not, to determine whether routine IABP insertion reduces major adverse cardiac and cardiovascular events (MACCE) in these patients.

The researchers found MACCE at hospital discharge in 23 (15.2 percent) of elective IABP recipients and 24 (16 percent) of those who did not receive IABP (P = .85). At six months, all-cause mortality was 4.6 and 7.4 percent in the two groups, respectively (P = .32). The IABP recipients experienced fewer major procedural complications than the other group (1.3 versus 10.7 percent; P < .001).

"Elective IABP insertion did not reduce the incidence of MACCE following PCI. These results do not support a strategy of routine IABP placement before PCI in all patients with severe left ventricular dysfunction and extensive coronary disease," the authors write.

The trial was sponsored by the British Cardiovascular Intervention Society, which received funds from Maquet Cardiovascular, Johnson & Johnson, and Cordis. Lilly provided abciximab for the trial.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: Genetic Variants Associated With End-Stage Renal Disease Next: Antiherpetic Antiviral Drugs Not Linked to Birth Defects

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.